Niagen Bioscience (NAGE) Debt to Equity (2016 - 2018)

Niagen Bioscience (NAGE) has 3 years of Debt to Equity data on file, last reported at $0.01 in Q4 2018.

• Debt to Equity for Q4 2018 came in at $0.01, down 12.46% year-over-year; the trailing twelve-month figure through Dec 2018 was $0.01 (down 12.46% YoY), and the FY2018 annual result was $0.01, down 12.46% from the prior year.
• Debt to Equity slipped to $0.01 in Q4 2018 per NAGE's latest filing, from $0.01 in the prior quarter.
• Over five years, Debt to Equity peaked at $0.92 in Q1 2016 and troughed at $0.01 in Q4 2018.
• A 3-year average of $0.24 and a median of $0.02 in 2016 frame the typical range for Debt to Equity.
• The sharpest annual moves came in 2016 and 2018: Debt to Equity sank 96.27% in 2016, then retreated 12.46% in 2018.
• A 3-year view of Debt to Equity shows it stood at $0.03 in 2016, then sank by 83.3% to $0.01 in 2017, then decreased by 12.46% to $0.01 in 2018.
• Business Quant data shows NAGE's Debt to Equity at $0.01 in Q4 2018, $0.01 in Q4 2017, and $0.03 in Q4 2016.